Bullish momentum and buybacks — GSK demonstrates strength above key moving averages

Traders Union
All News
Financial News
GSK rises 0.33% today to GBX 1,806

Highlights

GSK repurchased 203,000 shares at an average price of GBX 1,800.44, and 250,000 additional shares on November 28, 2025, via BNP Paribas.
By early December 2025, GSK’s treasury shares reached approximately 236.6 million, representing about 5.8% of total voting rights from 4.08 billion shares.
These buybacks are part of GSK’s ongoing £2 billion program initiated after FY 2024 results, demonstrating continued capital return to shareholders.

Treasury share buildup as robust buyback accelerates

GSK has continued the execution of its share buyback program, with notable activity including the repurchase of 203,000 shares at an average price of GBX 1,800.44 and a further 250,000 shares acquired on November 28, 2025, through BNP Paribas. By early December 2025, GSK's treasury shares reached approximately 236.6 million, representing around 5.8% of total voting rights out of 4.08 billion shares. This ongoing buyback is part of the £2 billion program launched after FY 2024 results.

Strong buying momentum as overbought signals increase caution

MACD and ADX both suggest strong bullish momentum, reflected in their "Strong Buy" and "Buy" signals. RSI remains constructive but not overbought, while D1 Stoch RSI stays neutral and CCI signals mild buying interest; however, BBP points to overbought territory and buyer dominance intraday. The Awesome Oscillator is neutral overall, providing limited directional confirmation. Today's session saw a very small negative gap at the open, with the current price situated near the upper end of today’s range amid moderate volatility. Momentum and intraday action are broadly aligned, but overbought signals and BBP caution that buyers may be overextended in the short run.

Upside consolidation likely as breakout risk remains elevated

For the coming week, the expected trading range is GBX 1,825 – 1,940, staying within ±8% of the current price and maintaining a bullish tilt. The probability of a price increase is very high (more than 80%), while a decline is much less likely. In the baseline scenario, GSK may consolidate between GBX 1,825 and GBX 1,900. A bullish breakout above GBX 1,940 could open the way for further gains toward new highs, while a drop below GBX 1,825 would expose the GBX 1,790 – 1,800 area as key support.

Viktoras Karapetjanc, senior analyst at Traders Union, sees robust demand supported by GSK’s ongoing buyback program and strong technical momentum. He believes institutional confidence remains high, with price levels staying well above key moving averages and supportive sentiment confirmed by the consistent pace of treasury share accumulation. The analyst expects the bullish structure to hold, with upward probability over 80% as the market prices in positive expectations following the FY 2024 results. He notes that intraday overbought signals warrant monitoring, but the broader trend is constructive. "GSK’s bullish setup remains intact, and I expect further appreciation as long as support above GBX 1,825 holds."

Previously it was reported that GSK maintained bullish momentum above key moving averages, with technical indicators such as the MACD and ADX confirming sustained buyer strength while RSI remained constructive and oscillators reflected mixed conditions. Short- and long-term support was identified by the Ichimoku Kijun and moving average levels, with the probability of a price increase viewed as elevated based on strong weekly technical signals.

Source of Data: GSK Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.